p. 5589−5594
2476-762X
Vol.16/No.14
p. 5595−5597
2476-762X
Vol.16/No.14
p. 5599−5605
2476-762X
Vol.16/No.14
p. 5607−5611
2476-762X
Vol.16/No.14
p. 5613−5618
2476-762X
Vol.16/No.14
p. 5619−5624
2476-762X
Vol.16/No.14
p. 5625−5633
2476-762X
Vol.16/No.14
wish > MDBK for the imported IFN,while for the Egyptian biosimillar locally produced one it was MDBK> Vero> wish. With regard to the antiviralactivity there was a significant difference of imported IFN potency compared with the locally produced IFN(P<0.05), the IFN potential (antiviral activity) was not cell line related and showed non-significant differencefor each separate product. Conclusions: Vero cells can be used as an alternative cell line for evaluation of IFNpotency in case of unavailable USP recommended cell lines. Alternative potency evaluation assay could be usedand proved significant difference in IFN potency in case of local and imported agents. Evaluation of antiviralactivity could be used in parallel to viral infectivity reduction assay for better accuracy. Mx gene can be used asa marker for IFN potential.]]>
p. 5635−5641
2476-762X
Vol.16/No.14
p. 5643−5645
2476-762X
Vol.16/No.14
G and +1135A>C polymorphisms were investigated with an amplification refractory mutationsystem and the HER2 Ile655Val polymorphism by restriction fragment length polymorphism. Significant riskassociations for PDGFB +286 GG (OR=5.25) and PDGFB +1135 CC (OR=3.19) genotypes were observed forGBC. Gender wise stratification revealed susceptibility for recessive models of PDGFB +1135A>C (OR=3.00) andHER2 Ile655Val (OR=2.52) polymorphisms among female GBC cases. GBC cases with gall stones were predisposedto homozygous +286 GG and +1135 CC genotypes. Significant risk associations were found for ACIle (OR=1.48),GAVal (OR=1.70), GAIle (OR=2.00) haplotypes with GBC cases and GCIle haplotype with female GBC cases(OR=10.37, P=<0.0001). Pair-wise linkage disequilibrium revealed negative associations among variant alleles.On multi-dimensional reduction analysis, a three factor model revealed significant gene-gene interaction forPDGFB +286A>G, PDGFB +1135A>C and HER2 Ile165Val SNPs with GBC. Protein-protein interaction showedsignificant association of PDGFB and HER2 with the epidermal growth factor receptor signaling pathway.]]>
p. 5647−5654
2476-762X
Vol.16/No.14
p. 5655−5661
2476-762X
Vol.16/No.14
Pro polymorphism and cancerrisk were inconclusive and conflicting for the Saudi population. Therefore, we performed a meta-analysis toinvestigate the relationship between the codon 72 Arg>Pro polymorphism and overall cancer risk in SaudiArabia. Materials and Methods: We searched all eligible published studies and data were pooled together toperform the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculatedfor homozygous, heterozygous, dominant and recessive genetic models. Results: A total of five eligible publishedstudies covering 502 cancer cases and 784 healthy controls were included in the meta-analysis. No publicationbias was detected in this study. The results suggested that the variant (Pro vs Arg: p=0.960; OR=1.004, 95%CI=0.852-1.183), homozygous (Pro.Pro vs Arg.Arg: p=0.970; OR=1.006, 95% CI=0.729-1.390), heterozygous(Arg.Pro vs Arg.Arg: p=0.473; OR=0.783, 95% CI=0.402-1.527) carriers were not associated with overall cancerrisk. Similarly, dominant (Pro.Pro+Pro.Arg vs Arg.Arg: p=0.632; OR=0.886, 95% CI=0.540-1.454) and recessive(Pro.Pro vs Pro.Arg+Arg.Arg: p=0.269; OR=1.163, 95%CI=0.890-1.521) models also did not indicate increasedrisk of cancer. Conclusions: The current meta-analysis suggests that the codon 72 Arg>Pro polymorphism ofthe p53 gene might not contribute to cancer susceptibility in Saudi population. Future well designed large casecontrol studies are needed to validate our findings.]]>
p. 5663−5667
2476-762X
Vol.16/No.14
p. 5669−5673
2476-762X
Vol.16/No.14
p. 5675−5679
2476-762X
Vol.16/No.14
p. 5681−5686
2476-762X
Vol.16/No.14
0.5 mg/dl) serum C-reactive protein (CRP) concentrations(p<0.001 each). Multivariate analysis showed that high serum CRP was independently associated with poorerPFS (p=0.040). Six month disease control rate (complete response, partial response and stable disease) in responseto sunitinib was significantly higher in patients with normal (≤0.5 mg/dl) than elevated baseline CRP (p<0.001).Conclusions: CRP is a significant independent predictor of PFS for Japanese patients with mCCRCC treatedwith first-line sunitinib. Pretreatment CRP concentration may be a useful biomarker predicting response tosunitinib treatment.]]>
p. 5687−5690
2476-762X
Vol.16/No.14
p. 5691−5695
2476-762X
Vol.16/No.14
p. 5697−5701
2476-762X
Vol.16/No.14
p. 5703−5707
2476-762X
Vol.16/No.14
2 cm,respectively. Tumor location was also significant for DM and OS, with 5-year rates of 69% vs 33% and 41% vs66% for trunk vs other locations, respectively. Conclusions: The natural course of a malignant skin melanomatreated radically is disadvantageous, with unsuccessful outcome in nearly half of the cases. Common clinicalfactors, such as Clark’s tumor stage, Breslow’s depth of invasion and the presence of metastatic nodes, have highprognostic significance. The size and location of the primary lesion may be considered independent prognosticfactors. The most important negative prognostic factor is the presence of metastatic regional lymph nodes. Onlyone quarter of patients with metastases in lymph nodes survive 5 years from primary surgery.]]>
p. 5709−5714
2476-762X
Vol.16/No.14
10 years inchildhood from 40.3± 12.0 years to 47.7± 13.9 in patients exposed for > 20years as adults. Among passive smokers,60.9% were premenopausal and 39.1% of patients were postmenopausal. In never smokers, 71.4% were postmenopausal. Expression of receptors in non-smokers vs passive smokers was comparable with no significantdifferences. Metastatic potential in lung parenchyma was slightlyelevated in passive smokers as compared tonever smokers although statistically non-significant. Conclusions: An inverse relationship exists between theintensity and duration of smoking and the age at presentation and poor prognostic factors. The results stronglysuggest efforts should be taken to prevent smoking, encourage quitting and restrict exposure to second handsmoke in India.]]>
p. 5715−5719
2476-762X
Vol.16/No.14
p. 5721−5726
2476-762X
Vol.16/No.14
p. 5727−5731
2476-762X
Vol.16/No.14
p. 5733−5739
2476-762X
Vol.16/No.14
p. 5741−5747
2476-762X
Vol.16/No.14
p. 5749−5754
2476-762X
Vol.16/No.14
p. 5755−5762
2476-762X
Vol.16/No.14
p. 5763−5766
2476-762X
Vol.16/No.14
G)]]>
C)]]>
G) and TP53 72 (G>C) genes are reported to increasethe susceptibility to head and neck cancer (HNC) in various populations. The risk for HNC is also stronglyassociated with etiologic habits such as smoking, alcohol consumption and/or chewing of betel quid (BQ). In acase-control study, we investigated the significance of the above polymorphisms alone, and upon interaction withone another as well as with various etiologic habits in determining HNC risk in a Northeast Indian population.Materials and Methods: Genotyping at 309 MDM2 and 72 TP53 in 122 HNC patients and 86 cancer free healthycontrols was performed by PCR using allele specific primers, and the results were confirmed by DNA sequencing.Results: Individuals with the GG mutant allele of MDM2 showed a higher risk for HNC in comparison to thosewith the TT wild type allele (OR=1.9, 95%CI: 1.1-3.3) (p=0.022). The risk was further increased in femalesby ~4-fold (OR=4.6, 95% CI: 1.1-19.4) (P=0.04). TP53 polymorphism did not contribute to HNC risk alone;however, interaction between the TP53 GC and MDM2 GG genotypes resulted in significant risk (OR=4.9, 95%CI: 0.2-105.1) (p=0.04). Smokers, BQ- chewers and alcohol consumers showed statistically significant and dosedependentincrease in HNC risk, irrespective of the MDM2 genotype. Conclusions: MDM2 genotype could serveas an important predictive biomarker for HNC risk in the population of Northeast India.]]>
p. 5767−5772
2476-762X
Vol.16/No.14
p. 5773−5777
2476-762X
Vol.16/No.14
p. 5779−5785
2476-762X
Vol.16/No.14
p. 5787−5792
2476-762X
Vol.16/No.14
p. 5793−5800
2476-762X
Vol.16/No.14
p. 5801−5805
2476-762X
Vol.16/No.14
p. 5807−5815
2476-762X
Vol.16/No.14
p. 5817−5822
2476-762X
Vol.16/No.14
p. 5823−5828
2476-762X
Vol.16/No.14
p. 5829−5834
2476-762X
Vol.16/No.14
p. 5835−5842
2476-762X
Vol.16/No.14
p. 5843−5846
2476-762X
Vol.16/No.14
p. 5847−5852
2476-762X
Vol.16/No.14
p. 5853−5858
2476-762X
Vol.16/No.14
p. 5859−5861
2476-762X
Vol.16/No.14
p. 5863−5868
2476-762X
Vol.16/No.14
p. 5869−5873
2476-762X
Vol.16/No.14
p. 5875−5881
2476-762X
Vol.16/No.14
p. 5883−5887
2476-762X
Vol.16/No.14
p. 5889−5897
2476-762X
Vol.16/No.14
p. 5899−5902
2476-762X
Vol.16/No.14
p. 5903−5906
2476-762X
Vol.16/No.14
p. 5907−5912
2476-762X
Vol.16/No.14
p. 5913−5916
2476-762X
Vol.16/No.14
p. 5917−5921
2476-762X
Vol.16/No.14
p. 5923−5931
2476-762X
Vol.16/No.14
p. 5933−5937
2476-762X
Vol.16/No.14
p. 5939−5944
2476-762X
Vol.16/No.14
p. 5945−5950
2476-762X
Vol.16/No.14
1/3 cervical stromal invasion (OR, 3.763; 95%CI,1.483-9.549). Conclusions: The rates of pathologic high-risk and intermediate-risk factors should be consideredand disclosed when counseling patients regarding primary treatment by RHPL. Oncologic outcomes of primarysurgical treatment for early-stage cervical carcinoma were found to be excellent.]]>
p. 5951−5956
2476-762X
Vol.16/No.14
p. 5957−5961
2476-762X
Vol.16/No.14
p. 5963−5966
2476-762X
Vol.16/No.14
p. 5967−5970
2476-762X
Vol.16/No.14
p. 5971−5976
2476-762X
Vol.16/No.14
p. 5977−5981
2476-762X
Vol.16/No.14
p. 5983−5986
2476-762X
Vol.16/No.14
p. 5987−5991
2476-762X
Vol.16/No.14
p. 5993−5999
2476-762X
Vol.16/No.14
p. 6001−6006
2476-762X
Vol.16/No.14
p. 6007−6010
2476-762X
Vol.16/No.14
p. 6011−6017
2476-762X
Vol.16/No.14
p. 6019−6026
2476-762X
Vol.16/No.14
T (rs2294008), PSCA G>A (rs2976392), MUC1A>G (rs4072037) and PLCE1 A>G (rs2274223) SNPs were genotyped by RT-PCR. Results: The distribution ofgenotypes for all four SNPs was in line with the Hardy-Weinberg equilibrium (rs2294008, P=0.153; rs2976392,P=0.269; rs4072037, P=0.609; rs2274223, P=0.858). The distribution of genotypes and alleles of PSCA C>T,PSCA G>A, MUC1 A>G and PLCE1 A>G SNPs was similar among controls and CRC patient groups (P>0.05).GG genotype of MUC1 SNP was more frequent in CRC patients (24.0%) than in controls (20.2%); however, thisassociation failed to reach significance (OR-1.45, P=0.15). Overall, in the present study SNPs of PSCA (rs2294008,rs2976392), MUC1 (rs4072037) and PLCE1 (rs2274223) genes were not associated with the presence of CRC.Conclusions: Gene polymorphisms of PSCA, PLCE1 and MUC1 genes are not associated with the presence ofCRC in European subjects.]]>
p. 6027−6032
2476-762X
Vol.16/No.14
p. 6033−6038
2476-762X
Vol.16/No.14
p. 6039−6046
2476-762X
Vol.16/No.14
p. 6047−6053
2476-762X
Vol.16/No.14
0.05. Conclusions: The study showed inappropriate use in breast cancerpatients because of non-compliance with duration, menopausal status and hormone receptor requirements. Toprescribe appropriate indication did not referred to the appropriate practice along the treatment. Drug useevaluation proved very useful for detecting the sign of inappropriate use and allows immediate feedback to thestakeholder for developing medication policy in the future. Importantly, there was no significantly difference inappropriate use of Letrozole across health benefit schemes.]]>
p. 6055−6059
2476-762X
Vol.16/No.14
p. 6061−6066
2476-762X
Vol.16/No.14
0.05). Due to the low number of samples we could not examine the relationship withclinicopathological features. However, bcl-2 expression may be important for prognostic outcome or a usefultarget for therapeutic intervention.]]>
p. 6067−6071
2476-762X
Vol.16/No.14
p. 6073−6080
2476-762X
Vol.16/No.14
p. 6081−6087
2476-762X
Vol.16/No.14
p. 6089−6092
2476-762X
Vol.16/No.14
p. 6093−6097
2476-762X
Vol.16/No.14
p. 6099−6104
2476-762X
Vol.16/No.14
8 hours per day, and current-smokers appeared to have decrease risk of CRC, but again these relationshipcould not be shown to be significantly associated (HRfam cancer= 0.96, 95% CI, 0.85-1.09, HRwork>8= 0.84,95% CI, 0.36-1.93, and HRcurrent-smoker = 0.51, 95% CI, 0.18-1.38). Conclusions: We found no evidence ofenvironmental factors effecting the risk of CRC. There is a need for further research to determine why factorsidentified risk in other populations appear to not be associated with CRC risk in Thais.]]>
p. 6105−6109
2476-762X
Vol.16/No.14
p. 6111−6116
2476-762X
Vol.16/No.14
p. 6117−6121
2476-762X
Vol.16/No.14
p. 6123−6128
2476-762X
Vol.16/No.14
p. 6129−6133
2476-762X
Vol.16/No.14
p. 6135−6140
2476-762X
Vol.16/No.14
p. 6141−6147
2476-762X
Vol.16/No.14
p. 6149−6154
2476-762X
Vol.16/No.14
p. 6155−6158
2476-762X
Vol.16/No.14
p. 6159−6162
2476-762X
Vol.16/No.14
p. 6163−6166
2476-762X
Vol.16/No.14
p. 6167−6169
2476-762X
Vol.16/No.14
p. 6171−6172
2476-762X
Vol.16/No.14
p. 6173−6174
2476-762X
Vol.16/No.14
p. 6175−6176
2476-762X
Vol.16/No.14